Global Liver Institute Offering Multilingual Materials and Grants for International NASH Day on June 10
04 mars 2021 09h24 HE
|
Global Liver Institute
Washington, DC, March 04, 2021 (GLOBE NEWSWIRE) -- Global Liver Institute (GLI) is pleased to announce that the 2021 International NASH Day (#NASHday) will be held on June 10, 2021, with the theme,...
Surrozen Awarded NIH Grant to Support Development of SZN-043, a Liver-Specific Regenerative Antibody, for the Treatment of Severe Alcoholic Hepatitis
15 oct. 2020 07h00 HE
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, has been awarded an NIH grant to...
89bio Announces Positive Topline Results from its Phase 1b/2a Trial of BIO89-100 in NASH
14 sept. 2020 07h01 HE
|
89bio, Inc.
All dose groups achieved statistically significant reductions in liver fat, with relative reductions of up to 60% versus baseline and up to 70% versus placebo Favorable safety and...
89bio Announces Proposed Public Offering of Common Stock
06 juil. 2020 06h30 HE
|
89bio, Inc.
SAN FRANCISCO, July 06, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
Surrozen Announces Publication of Two Abstracts Providing Evidence for Liver-Targeted Tissue Regeneration
04 mai 2020 10h00 HE
|
Surrozen, Inc.
-- Abstracts originally accepted for 2020 Digestive Disease Week Conference – to be published online -- SOUTH SAN FRANCISCO, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a...
89bio Announces Closing of Enrollment in its Phase 1b/2a NASH Trial and Reports New Preclinical Data Confirming BIO89-100’s Mechanism of Action Via Potent FGF Receptor Agonism
13 avr. 2020 08h30 HE
|
89bio, Inc.
- Closed enrollment in its Phase 1b/2a NASH trial with 98% of patients enrolled and delays initiation of its SHTG trial due to the COVID-19 pandemic; Reaffirms guidance for NASH trial topline data in...
89bio Appoints Healthcare Industry Veteran Steven Altschuler, M.D., as Chairman of the Board of Directors
25 mars 2020 16h05 HE
|
89bio, Inc.
SAN FRANCISCO, March 25, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89bio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
18 mars 2020 16h05 HE
|
89bio, Inc.
- BIO89-100 Phase 1b/2a NASH study on track for topline data in 2H20 - - Initiation of Phase 2 SHTG study planned in 1H20 - SAN FRANCISCO, March 18, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq:...
89bio to Present at the SVB Leerink 9th Annual Global Healthcare Conference
21 févr. 2020 16h05 HE
|
89bio, Inc.
SAN FRANCISCO, Feb. 21, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
Novel Probiotic-Prebiotic supplement blend supports a healthy liver
23 janv. 2020 10h00 HE
|
Life Extension
Fort Lauderdale, Fla., Jan. 23, 2020 (GLOBE NEWSWIRE) -- Because liver health is vital at any age, Life Extension® has developed a novel approach to supporting a healthy liver. FLORASSIST® Liver...